LEADER 01635oam  2200445I  450 
001 9910704009603321
005 20151112155555.0
035   $a(CKB)5470000002437563
035   $a(OCoLC)846903715
035   $a(EXLCZ)995470000002437563
100   $a20130606d2013      ua             0
101 0 $aeng
135   $aurbn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 14$aThe effect of generic drug competition on generic drug prices during the Hatch-Waxman 180-day exclusivity period /$fLuke M. Olson, Brett W. Wendling
210  1$aWashington, DC :$cBureau of Economics, Federal Trade Commission,$d2013.
215   $a1 online resource (41 unnumbered pages) $cillustrations
225 1 $aWorking paper ;$vno. 317
300   $aTitle from title screen (viewed on June 6, 2013).
300   $a"April 2013."
320   $aIncludes bibliographical references.
606   $aGeneric drugs$xEconomic aspects$zUnited States
606   $aGeneric drugs$xPrices$zUnited States
606   $aDrugs$xPrices$zUnited States
615  0$aGeneric drugs$xEconomic aspects
615  0$aGeneric drugs$xPrices
615  0$aDrugs$xPrices
700   $aOlson$b Luke M.$01420553
702   $aWendling$b Brett W.
712 02$aUnited States.$bFederal Trade Commission.$bBureau of Economics,
801  0$bAZS
801  1$bAZS
801  2$bOCLCQ
801  2$bGPO
906   $aBOOK
912   $a9910704009603321
996   $aThe effect of generic drug competition on generic drug prices during the Hatch-Waxman 180-day exclusivity period$93538877
997   $aUNINA